Last reviewed · How we verify
Insulin VIAject™ (90%)
Insulin VIAject is a rapid-acting insulin formulation designed to achieve faster absorption and onset of action compared to standard insulin injections.
Insulin VIAject is a rapid-acting insulin formulation designed to achieve faster absorption and onset of action compared to standard insulin injections. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin VIAject™ (90%) |
|---|---|
| Sponsor | Biodel |
| Drug class | Rapid-acting insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
VIAject uses Biodel's proprietary VIA (Velocity and Insulin Administration) technology to enhance insulin absorption through the addition of excipients that modify subcutaneous tissue permeability. This allows insulin to enter the bloodstream more quickly, reducing the time to peak concentration and potentially improving postprandial glucose control in diabetic patients.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
Key clinical trials
- Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles (NA)
- Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |